Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWD-ASPECT
2022-502239-20-00Phase 4Authorised
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF) comparing Spironolactone arm with Eplerenone arm (2 arms). Primary endpoint: All-cause mortality. Planned start Jan 2023; status: authorised.
02
Drugs
spironolactoneeplerenone
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2022-502239-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502239-20-00.